ALXN Alexion Pharmaceuticals Inc.

117
+2.71  (+2%)
Previous Close 114.29
Open 115.14
Price To Book 2.85
Market Cap 26102305944
Shares 223,096,632
Volume 2,472,844
Short Ratio
Av. Daily Volume 1,714,168

SEC filingsSee all SEC filings

  1. 8-K - Current report 181248250
  2. CT ORDER - Confidential treatment order 181237437
  3. 8-K - Current report 181188627
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181176063
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181136698

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 primary endpoint met - September 24, 2018.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 data due early 2019.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
FDA approval announced December 21, 2018.
ULTOMIRIS (ravulizumab-cwvz)
Paroxysmal nocturnal hemoglobinuria (PNH)
Approval announced October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)
Phase 3 trial is enrolling.
WTX101
Wilson disease

SEC Filings

  1. 8-K - Current report 181248250
  2. CT ORDER - Confidential treatment order 181237437
  3. 8-K - Current report 181188627
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181176063
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181136698
  6. 8-K - Current report 181135237
  7. 8-K - Current report 181098576
  8. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181018925
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18972206
  10. 8-K - Current report 18970097